自体NK细胞治疗恶性肿瘤有效性和安全性的系统评价

Efficacy and safety of autologous NK cells for the treatment of malignant tumors:a systematic review

目的系统评价自体自然杀伤细胞(natural killer cell,NK)治疗恶性肿瘤的有效性和安全性。方法计算机检索PubMed、Web of Science、Embase数据库,搜集有关自体NK细胞治疗恶性肿瘤的临床研究,检索时限均从建库至2023年7月1日。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,对结果进行描述性分析。结果共纳入15个研究,肿瘤类型最多为非小细胞肺癌。NK细胞注射剂量通常在7.0×10^(7)至7.0×10^(9)细胞总量,疗程间隔14~21天,次数通常为3~6次。NK细胞治疗的总缓解率为0%~77.78%。主要不良反应为发热(3.98%)、疲劳(1.99%)、皮疹(0.4%)、头晕(1.20%)。结论当前证据显示,自体NK细胞治疗恶性肿瘤安全,部分研究显示NK细胞治疗具有缓解作用。受纳入研究数量和质量的限制,上述结论尚待更多高质量研究予以验证。

Objective To systematically review the efficacy and safety of autologous natural killer cells(NK)cells for the treatment of malignant tumors.Methods The PubMed,Web of Science,and Embase databases were electronically searched to collect clinical studies on autologous NK cells for the treatment of malignant tumors from inception to July 1,2023.Two reviewers independently screened literature,extracted data and assessed the risk of bias of the included studies.Descriptive analysis of the results were conducted.Results A total of 15 studies were included.The most common tumor type was non-small cell lung cancer.The dose of NK cell injections usually ranged from 7.0×10^(7) to 7.0×10^(9) cells,with a treatment interval of 14-21 days and a frequency of 3-6 injections.The overall response rate for NK cell therapy ranged from 0%to 77.78%.The main adverse effects were fever(3.98%),fatigue(1.99%),rash(0.4%),and dizziness(1.20%).Conclusion Current evidence shows that autologous NK cell therapy is safe for treating malignant tumors,and some studies have shown that NK cell therapy has a relieving effect.Due to the limited quality and quantity of the included studies,more high-quality studies are needed to verify above conclusion.